Chidamide Market 2028 By Type, Application and Geography | The Insight Partners

report image

Chidamide Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (5 mg, Others); Application (PECL Treatment, Other Cancers Treatment) and Geography

Report Code: TIPRE00023440 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming


Chidamide is also known as CS055, and HBI-8000 is a subtype-selective benzamide HDAC (histone deacetylase) inhibitor. It increases histone H3 acetylation levels in colon cancer cells. It is a potential therapeutic drug used in the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL) cancer and various cancers such as hepatocellular carcinoma, hematological cancer, and bladder tumor. Chidamide not only inhibits tumor cells proliferation directly but also enhances the cellular immunity ability in various kinds of tumors.


The "Global Chidamide Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the chidamide market with detailed market segmentation by type, application, and geography. The report provides key statistics on the market status of the leading chidamide market players and offers key trends and opportunities in the market.


  •  Based on type, the global chidamide market is segmented into 5 mg and others.
  •  On the basis of application, the market is bifurcated into PECL treatment and other cancers treatment.


  •  The increasing prevalence of cancer, growing aging population, and unhealthy lifestyle such as smoking drive the demand for the chidamide market.
  •  Increasing investment in research and development activities by major pharmaceutical companies fuels the market growth.
  •  Improving healthcare facilities in developing economies propel market growth.


  •  High cost of drug.


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The chidamide market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the chidamide market in these regions.


COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. Due to increasing cases of Covid-19, the government of many countries imposed lockdown, shutdown business resulting in trade disruptions, supply chain disruptions. Elective surgeries were also canceled to prevent virus transmission, and only emergency procedures were allowed to be carried out. This affected the chidamide market growth, as the drug demand was impacted. Although, after the removal of the restrictive measures, the market may witness slow growth in the future.

Get more information on this report :


The report covers key developments in the chidamide market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from chidamide market are anticipated to have lucrative growth opportunities in the future with the rising demand for chidamide in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the chidamide market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •  Shenzhen Chipscreen
  •  HuyaBio
  •  GNT Biotech Medicals Corporation
  •  Japan Eisai
  •  Spectrum Pharmaceuticals
  •  Celegne
  •  Hutchison MediPharma
  •  Axon Medchem

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Get more information on this report :

The List of Companies

1.Shenzhen Chipscreen
3.GNT Biotech Medicals Corporation
4.Japan Eisai
5.Spectrum Pharmaceuticals
7.Hutchison MediPharma
8.Axon Medchem
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market


Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000 $2700
  • $4550 $4095
  • $6550 $5568
  • $8550 $6840

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount